Harvard consortium blueprints $50M cell and gene therapy center — but can they actually foster lower drug prices?
Harvard is spearheading a consortium that has set out to build a $50 million center aimed at quickening the development of new and far more efficient cell and gene therapies in the booming Boston biotech hub. And the group plans to move fast.
The Center for Advanced Biological Innovation and Manufacturing is aiming at building a 30,000 to 40,000 square foot facility in Boston where drug hunters can work on next-gen therapies in the field — like the off-the-shelf CAR-T drugs looking to supplant the complex autologous pioneers now on the market.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.